- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.03. | THERALINK TECHNOLOGIES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.02. | THERALINK TECHNOLOGIES, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.02. | THERALINK TECHNOLOGIES, INC. - 10-K/A, Annual Report | 1 | SEC Filings | ||
| 15.02. | THERALINK TECHNOLOGIES, INC. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
| 29.12.23 | THERALINK TECHNOLOGIES, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 1 | SEC Filings | ||
| 18.12.23 | Theralink Technologies, Inc.: Theralink announces groundbreaking RPPA study by partner GMU - reveals novel therapy options for hard-to-treat breast cancer patients that could lead to significant improvements in response rates | 270 | GlobeNewswire (Europe) | Golden, Colorado & Nashville, Tennessee, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies (OTC: THER), a precision oncology company with an exclusively licensed commercial RPPA (reverse phase... ► Artikel lesen | |
| 28.11.23 | THERALINK TECHNOLOGIES, INC. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.23 | Theralink Technologies, Inc.: Theralink and IMAC Holdings announce receipt and response to the Securities and Exchange Commission comments on the previously filed Form S4 | 136 | GlobeNewswire (Europe) | Golden, Colorado & Nashville, Tennessee, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies, Inc. (OTC: THER) ("Theralink"), a precision oncology company with its exclusive commercial RPPA (reverse... ► Artikel lesen | |
| 03.11.23 | Theralink Technologies, Inc.: Theralink Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute's Molecular Tumor Board | 190 | GlobeNewswire (Europe) | Golden, Colorado, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies, Inc. (OTC: THER) ("Theralink"), a precision oncology company with its exclusive commercial RPPA (reverse phase protein array)... ► Artikel lesen | |
| 04.10.23 | Theralink Technologies, Inc.: Theralink Announces Filing of Form S-4; Merger with IMAC Holdings Expected During Q4 2023 | 415 | GlobeNewswire (Europe) | Golden, Colorado, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies, Inc. (OTC: THER) ("Theralink" or the "Company"), a precision oncology company with a novel phosphoprotein and protein assay... ► Artikel lesen | |
| 27.06.23 | Theralink Technologies, Inc.: Theralink Technologies Appoints Faith Zaslavsky as Chief Executive Officer | 300 | GlobeNewswire (Europe) | Golden, Colorado, June 27, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies, Inc. (OTC: THER) ("Theralink" or the "Company"), a precision oncology company with a novel phosphoprotein and protein assay... ► Artikel lesen | |
| 23.05.23 | IMAC Holdings, Inc.: Theralink Signs Definitive Merger Agreement to be Acquired by IMAC Holdings, a Nasdaq Listed Company | 478 | GlobeNewswire (Europe) | Theralink's patented technology is helping to solve a significant problem in cancer treatment by providing game changing technology that can predict FDA-approved drugs that may be effective in each... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 9,160 | -4,98 % | Evotec-Aktie: Wann kommt die Trendwende? | Wenige Tage vor der Bekanntgabe neuer Geschäftszahlen kommt die Evotec-Aktie (WKN: 566480) ihrem 12-Monats-Tief, das bei 12,62 € liegt, gefährlich nahe. Während ein Analyst eine frische Kaufempfehlung... ► Artikel lesen | |
| QIAGEN | 37,940 | -1,65 % | QIAGEN N.V.: QIAGEN erweitert Tuberkulose-Portfolio: Neues NGS-Panel unterstützt Echtzeit-Überwachung und Bekämpfung antimikrobieller Resistenzen | QIAseq xHYB Mycobacterium tuberculosis Panel zu Forschungszwecken ermöglicht kulturfreies Whole Genome Sequencing komplexer Proben // Panel beschleunigt Nachverfolgung von TB-Ausbrüchen und unterstützt... ► Artikel lesen | |
| VERA THERAPEUTICS | 38,690 | -3,15 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
| IMMUNOVANT | 27,750 | 0,00 % | Should You Hold Immunovant (IMVT)? | ||
| KYMERA THERAPEUTICS | 33,350 | 0,00 % | Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) | ||
| RECURSION PHARMACEUTICALS | 7,840 | 0,00 % | Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX | ||
| ARCTURUS THERAPEUTICS | 26,170 | -3,00 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 44,200 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | ||
| ARCUTIS BIOTHERAPEUTICS | 8,590 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Appoints David Topper as Chief Financial Officer | WESTLAKE VILLAGE, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage company focused on developing meaningful innovations in immuno-dermatology... ► Artikel lesen | |
| DYNE THERAPEUTICS | 23,695 | -5,14 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer | WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 13,210 | 0,00 % | Day One Biopharmaceuticals, Inc.: Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor | First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation RAPNO LGG overall response rate... ► Artikel lesen | |
| KEROS THERAPEUTICS | 54,19 | 0,00 % | Prozessmanagement in der Gemeinschaftsverpflegung / Keros Consult optimiert Warenwirtschaft für Eichhof-Stiftung Lauterbach | Düsseldorf (ots) - Ab sofort unterstützt Keros Consult, eine hundertprozentige Tochtergesellschaft der Klüh-Gruppe, die Eichhof-Stiftung Lauterbach bei der Optimierung ihrer Bestell- und Produktionsprozesse... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,600 | 0,00 % | Expert Ratings For Beam Therapeutics | ||
| SANA BIOTECHNOLOGY | 8,500 | -0,93 % | Sana Biotechnology, Inc. - 8-K, Current Report | ||
| ARVINAS | 31,600 | -2,89 % | Arvinas Inc.: Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer | NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today... ► Artikel lesen |
Das Unternehmen THERALINK TECHNOLOGIES INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
